Salford Royal Nhs Foundation Trust

Salford M68HD

2 studies enrolling now · 33 studies all time

What they study most

ADPKD, Acid Maltase Deficiency, Atopic Dermatitis, Autosomal Dominant Polycystic Kidney, Cervical Dystonia, Citrin Deficiency, Clear Cell Renal Cell Carcinoma, Diabetic Nephropathies, Diffuse Cutaneous Systemic Sclerosis, Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Fabry Disease

Studies at this site

• Study of WAL0921 in Patients With Glomerular Kidney Diseases — Recruiting now
• A Global Prospective Observational Registry of Patients With Pompe Disease — Recruiting now
• A Fabry Disease Gene Therapy Study — Stopped early
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• Multi-omics Study in Citrin Deficiency — Running, not enrolling
• Rostock International Parkinson's Disease Study (ROPAD) — Completed
• A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) — Completed
• First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 — Completed
• A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease — Completed
• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis — Completed
• AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• Entyvio (Vedolizumab) Long Term Safety Study — Completed
• A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) — Completed
• Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function — Completed
• A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency — Stopped early
• Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease — Completed
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease — Stopped early
• Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) — Completed
• Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) — Completed
• UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder — Stopped early
• InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study — Completed
• Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease — Completed
• Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome — Completed
• Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis — Stopped early
• A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. — Completed
• A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures — Completed
• BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study) — Stopped early
• Extension Study for Patients Who Have Participated in a BMN 701 Study — Stopped early
• A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis — Completed
• A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation — Stopped early